Melane Sampson, Author at BioTuesdays

Developments

FDA clears Vifor, Cara pruritus injection associated with CKD

The FDA approved an NDA from Vifor Pharma and Cara Therapeutics (NASDAQ:CARA) for their KORSUVA injection for the treatment of moderate-to-severe pruritus (itch) associated with chronic kidney disease in adults...

August 24, 2021

Developments

PharmaJet needle free system cleared for first plasmid DNA COVID-19 vaccine

Closely-held PharmaJet announced that its partner, Zydus Cadila, has received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world’s first plasmid DNA vaccine for...

August 23, 2021

Markets

AGP cuts IMAC to neutral; PT to $1.75 from $2.35

Alliance Global Partners downgraded IMAC Holdings (NASDAQ:IMAC) to “neutral” and reduced its price target to $1.75 from $2.35 after the Center for Medicare and Medicaid Services (CMS) requested repayment of $2.9-million...

August 19, 2021

Developments

111, Inc. deepens partnership with Bayer

111, Inc. (NASDAQ:YI) has expanded its existing partnership with Bayer Healthcare in China. The original partnership was signed in September 2020 and involved collaborating on drug commercialization initiatives in China...

August 16, 2021

Markets

WB starts Sera Prognostics at OP

William Blair launched coverage of Sera Prognostics (NASDAQ:SERA), a pregnancy diagnostics company, with an “outperform” rating. The stock closed at $12.85 on Aug. 6. Analyst Brian Weinstein writes that the current rate...

August 9, 2021

Developments

Profound Medical posts sequential 145% jump in Q2 recurring revenue

Profound Medical (NASDAQ:PROF; TSX:PRN) reported a 145% increase in recurring revenue for the second quarter, compared with the first quarter of 2021. Total revenue, including capital sales outside of the U.S...

August 5, 2021

Markets

111 Inc. named to top 10 leaders of China’s new pharma retail industry

111 Inc. (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, was named as one of the top 10 leaders of China’s new...

July 30, 2021

Developments

Deep Genomics raises $180-million (U.S.) to develop drugs discovered by AI

University of Toronto spinout, Deep Genomics, raised $180-million (U.S.) led by Softbank’s Vision Fund 2 to bankroll its efforts to discover and develop drugs using artificial intelligence. The funding group included...

July 28, 2021

Developments

FDA clears Asensus Surgical 510(k) for articulating instruments

Asensus Surgical (NYSE American:ASXC) received FDA 510(k) clearance for 5 mm diameter articulating instruments, adding to the Senhance Surgical System robotic technology platform. Articulating instruments offer better...

July 28, 2021

Developments

Cybin receives conditional listing approval from NYSE American

Cybin (NEO:CYBN; OTCQB:CLXPF) has received conditional listing approval from the NYSE American stock exchange, under the ticker symbol, CYBN. In a statement, Doug Drysdale, CEO of Cybin, said conditional listing...

July 22, 2021

Author - Melane Sampson

FDA clears Vifor, Cara pruritus injection associated with CKD

PharmaJet needle free system cleared for first plasmid DNA COVID-19 vaccine

AGP cuts IMAC to neutral; PT to $1.75 from $2.35

111, Inc. deepens partnership with Bayer

WB starts Sera Prognostics at OP

Profound Medical posts sequential 145% jump in Q2 recurring revenue

111 Inc. named to top 10 leaders of China’s new pharma retail industry

Deep Genomics raises $180-million (U.S.) to develop drugs discovered by AI

FDA clears Asensus Surgical 510(k) for articulating instruments

Cybin receives conditional listing approval from NYSE American

Subscribe